TREATMENT PATTERNS AND GLYCEMIC OUTCOMES OF REAL-WORLD SGLT2-INHIBITORS BASED THERAPIES IN TYPE 2 DIABETES: A MULTICENTRIC STUDY FROM INDIA

bjectives: This study aimed to describe the real-life use of sodium-glucose cotransporter-2 (SGLT2) inhibitor-based therapies as well as assess their effect on glycated hemoglobin (HbA1c) levels in individuals with type 2 diabetes mellitus (T2DM). Methods: A prospective observational study was carried out from 6 diabetes centers (five in Pune, Maharashtra, and one in Trichy, Tamil Nadu). A total of 500 adults whose diabetes was being treated with an SGLT2 inhibitor alone or in combination with other antidiabetic drugs were enrolled. Treatment details, baseline characteristics, and HbA1c values at enrollment and at 26 weeks were recorded. Changes in HbA1c were reported using descriptive statistics and appropriate comparative statistical tests in the computer package, Version 26 of the software package, the Statistical Package for Social Sciences. Results: The mean HbA1c at baseline was 8.93±1.8% which was reduced to 7.36±1.4% at 26 weeks of therapy (mean reduction: 1.57%, p